Related Experiment Videos
Malignant external otitis: treatment with fluoroquinolones.
H Z Joachims1, J Danino, R Raz
1Department of Otolaryngology, Rambam Medical Center, Haifa, Israel.
American Journal of Otolaryngology
|May 1, 1988
Summary
Malignant external otitis (MEO) is a serious condition. Ciprofloxacin, a new antibiotic, shows promise for treating MEO cases resistant to standard therapies, offering a potential new treatment option.
Area of Science:
- Infectious Diseases
- Otolaryngology
- Pharmacology
Background:
- Malignant external otitis (MEO) presents a significant mortality risk.
- Prompt diagnosis and early intervention are critical for successful MEO treatment.
- Standard MEO treatment involves prolonged antibiotics and surgery, with hyperbaric oxygen for refractory cases.
Observation:
- This study reports on four MEO cases unresponsive to conventional treatments.
- Ciprofloxacin, a novel fluoroquinolone, was administered to these refractory MEO patients.
- The efficacy of Ciprofloxacin against Pseudomonas aeruginosa, a common MEO pathogen, is well-established.
Findings:
- Ciprofloxacin demonstrated successful treatment outcomes in four previously refractory MEO cases.
- This marks the initial documentation of Ciprofloxacin's use in treating MEO.
- The broad-spectrum activity of Ciprofloxacin includes key MEO-associated bacteria.
Implications:
- Ciprofloxacin represents a potential new therapeutic agent for difficult-to-treat MEO.
- Further research may establish Ciprofloxacin as a frontline treatment for MEO.
- This finding could improve outcomes for patients with severe external ear infections.